Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
2026-01-27 10:49:48
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER
OF ANY OF THE SECURITIES DESCRIBED HEREIN.
Oslo, Norway, 27 January 2026: Reference is made to the stock exchange
announcements published by Lytix Biopharma AS ("Lytix" or the "Company") on 9
January 2026 and 26 January 2026, regarding the successful completion of a
private placement (the "Private Placement") of new shares raising approximately
NOK 61 million in gross proceeds, and a subsequent offering (the "Subsequent
Offering") with non-tradeable subscription rights (the "Subscription Rights"),
of up to 3,333,333 new shares (the "Offer Shares"), at NOK 9.00 per share,
raising gross proceeds of up to NOK 30 million.
The Subsequent Offering, which was approved by the Company's extraordinary
general meeting on 26 January 2026, will be directed towards existing
shareholders in the Company as of 8 January 2026 (as registered in the VPS two
trading days thereafter (the "Record Date")), who (i) were not included in the
pre-sounding phase of the Private Placement, (ii) were not allocated shares in
the Private Placement, and (iii) are not resident in a jurisdiction where such
an offering would be unlawful or would, in jurisdictions other than Norway,
require any prospectus, filing, registration or similar action (jointly, the
"Eligible Shareholders").
Publication of Prospectus regarding Subsequent Offering
The Company announces that a national prospectus dated 25 January 2026 relating
to the Subsequent Offering (the "Prospectus") has been registered with the
Norwegian Register of Business Enterprises in accordance with section 7-8 of the
Norwegian Securities Trading Act. The Prospectus is now available at the
Company's website https://www.lytixbiopharma.com/.
Neither the Financial Supervisory Authority of Norway nor any other public
authority has carried out any form of review, control, or approval of the
Prospectus. The Prospectus does not constitute an EEA-prospectus.
Eligible Shareholders will receive 0.098381 Subscription Rights for every
existing Share registered as held by such Eligible Shareholder on the Record
Date, rounded down to the nearest whole Subscription Right. The Subscription
Rights will be registered in the VPS under ISIN NO0013712851.
Each whole Subscription Right will, subject to applicable law, entitle the
holder to subscribe for and be allocated one Offer Share in the Subsequent
Offering. Over-subscription is permitted